Table 2.

Association between selected polymorphisms and the risk of developing malignant mesothelioma

SNP	Genotype	Controls N (%)	MM N (%)	OR (95% CI)	p	OR (95% CI)adj1	padj1	OR (95% CI)adj2	padj2
IL1B rs1143623	GG	88 (50.3)	152 (54.9)	reference		reference
	GC	67 (38.3)	97 (35.0)	0.84 (0.56–1.26)	0.396	0.82 (0.52–1.29)	0.388	0.56 (0.29–1.05)	0.072
	CC	20 (11.4)	28 (10.1)	0.81 (0.43–1.52)	0.514	0.69 (0.35–1.38)	0.294	0.34 (0.11–1.04)	0.060
	GC+CC	87 (49.7)	125 (45.1)	0.83 (0.57–1.22)	0.341	0.79 (0.52–1.20)	0.266	0.50 (0.28–0.92)	0.025
IL1B rs16944	TT	21 (12.0)	36 (13.0)	1.10 (0.60–2.02)	0.756	0.94 (0.48–1.82)	0.849	0.53 (0.20–1.43)	0.210
	TC	75 (42.9)	118 (42.6)	1.01 (0.67–1.51)	0.960	0.98 (0.63–1.52)	0.911	0.67 (0.36–1.24)	0.198
	CC	79 (45.1)	123 (44.4)	reference		reference
	TC+TT	96 (54.9)	154 (55.6)	1.03 (0.70–1.51)	0.878	0.97 (0.64–1.47)	0.873	0.63 (0.35–1.13)	0.122
IL1B rs1071676	GG	105 (60.0)	165 (59.6)	reference		reference
	GC	60 (34.3)	98 (35.4)	1.04 (0.69–1.56)	0.851	0.97 (0.62–1.51)	0.895	1.00 (0.53–1.89)	0.993
	CC	10 (5.7)	14 (5.1)	0.89 (0.38–2.08)	0.789	0.96 (0.38–2.41)	0.931	2.03 (0.70–5.90)	0.194
	GC+CC	70 (40.0)	112 (40.4)	1.02 (0.69–1.50)	0.927	0.97 (0.64–1.48)	0.885	1.15 (0.64–2.08)	0.632
MIR146A rs2910164	GG	94 (53.7)	158 (57.0)	reference		reference
	GC	64 (36.6)	110 (39.7)	1.02 (0.69–1.53)	0.913	0.91 (0.59–1.41)	0.672	0.67 (0.36–1.25)	0.209
	CC	17 (9.7)	9 (3.2)	0.31 (0.13–0.73)	0.008	0.34 (0.14–0.85)	0.020	0.39 (0.11–1.38)	0.144
	GC+CC	81 (46.3)	119 (43.0)	0.87 (0.60–1.28)	0.488	0.79 (0.52–1.21)	0.278	0.62 (0.34–1.11)	0.109

adj1 = adjustment for age and gender; adj2 = adjustment for age, gender and asbestos exposure; CI = confidence interval; MM = malignant mesothelioma; OR = odds ratio; SNP = single nucleotide polymorphism